PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28415776-0	2017	Targeting protein homeostasis with nelfinavir/salinomycin dual therapy effectively induces death of mTORC1 hyperactive cells.	salinomycin	46-57	CREB regulated transcription coactivator 1	Mus musculus	100-106	
24905570-0	2014	Salinomycin suppresses LRP6 expression and inhibits both Wnt/beta-catenin and mTORC1 signaling in breast and prostate cancer cells.	salinomycin	0-11	CREB regulated transcription coactivator 1	Mus musculus	78-84	
24905570-4	2014	In the present study, we found that LRP6 overexpression induced mTORC1 signaling activation in cancer cells, and that salinomycin was not only a potent Wnt/beta-catenin signaling inhibitor, but also a strong mTORC1 signaling antagonist in breast and prostate cancer cells.	salinomycin	118-129	CREB regulated transcription coactivator 1	Mus musculus	208-214	
24905570-6	2014	Moreover, salinomycin was able to suppress the expression of cyclin D1 and survivin, two targets of both Wnt/beta-catenin and mTORC1 signaling, in prostate and breast cancer cells, and displayed remarkable anticancer activity.	salinomycin	10-21	CREB regulated transcription coactivator 1	Mus musculus	126-132	
28415776-9	2017	Sporadic cancer cell lines with hyperactive mTORC1 signalling were also susceptible to this nelfinavir/salinomycin drug combination.	salinomycin	103-114	CREB regulated transcription coactivator 1	Mus musculus	44-50	
28415776-4	2017	We found a nelfinavir and salinomycin combination specifically killed TSC2-deficient, mTORC1 hyperactive cells.	salinomycin	26-37	CREB regulated transcription coactivator 1	Mus musculus	86-92	
27557496-0	2016	Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.	salinomycin	50-61	CREB regulated transcription coactivator 1	Mus musculus	40-46	
27557496-3	2016	We report that the antibiotic salinomycin, a cancer stem cell blocker, is a dual-acting AR and mTORC1 inhibitor, inhibiting PTEN-deficient castration-sensitive and castration-resistant prostate cancer in culture and xenograft tumors.	salinomycin	30-41	CREB regulated transcription coactivator 1	Mus musculus	95-101	
27557496-12	2016	Our novel finding on dual inhibition of AR and mTORC1 suggests that salinomycin is potentially active as monotherapy against advanced prostate cancer.	salinomycin	68-79	CREB regulated transcription coactivator 1	Mus musculus	47-53